Cooper Companies (COO) Stock Could Be 24.4% Undervalued After Q2 Earnings Beat

Cooper Companies (COO) is back on investors’ radar after its Q2 2026 earnings release, where both revenue and adjusted EPS exceeded Wall Street estimates, and the stock moved sharply higher on the news.

See our latest analysis for Cooper Companies.

For context, Cooper Companies’ share price has risen 7.3% over the past month after the earnings surprise, but is still down 18.7% year to date, while the 1 year total shareholder return is down 5.6%. This points to improving short term momentum after a weaker multi year run.

If this earnings reaction has you thinking about where else confidence might be building, it is a good time to scan the market for other healthcare related opportunities like 41 healthcare AI stocks.

So with Cooper Companies stock trading at a discount to both some intrinsic value estimates and the average analyst price target, you have to ask: is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 24.4% Undervalued

On the most followed fair value view, Cooper Companies stock at $65.91 is set against an implied value of about $87, with that gap resting on a detailed earnings and cash flow story.

Free cash flow is poised to inflect higher as a multi-year capital expenditure cycle winds down following the ramp-up of MyDAY capacity, with management guiding for approximately $2 billion in free cash flow over the next three years. This improved cash generation, tied to strong cost discipline and revenue momentum, will further benefit shareholders via debt reduction and share repurchases.

Read the complete narrative.

Curious what has to happen inside Cooper Companies for that kind of cash flow and earnings profile to line up with the modelled fair value? The narrative leans on a specific mix of revenue growth, margin expansion, and a lower future earnings multiple to support that figure, plus a clear view on how many shares will be left on the register. The full breakdown spells out those moving parts in black and white.

Result: Fair Value of $87.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Cooper Companies still faces pressure from slower growth in the contact lens market and pricing competition, as well as uncertainty around the Clariti to MyDAY transition and softer fertility and IUD demand.

Find out about the key risks to this Cooper Companies narrative.

Another View on Cooper Companies Stock

The earlier narrative focuses on cash flows and an analyst fair value of $87.14, which suggests Cooper Companies may appear undervalued at $65.91. The picture changes when you look at the P/E ratio, where the stock trades at 54.5x earnings.

That 54.5x multiple is significantly higher than the company’s own fair ratio estimate of 32.5x, the peer average of 23.1x, and the US Medical Equipment industry at 24.4x. This gap indicates investors are already paying a premium, so the key question is whether you believe future earnings can comfortably support that kind of valuation.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern running through this Cooper Companies story, consider reviewing the underlying data for yourself promptly and then weigh up the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Cooper Companies?

If Cooper Companies has you rethinking your portfolio, do not stop here. Broaden your watchlist with other clear, data backed ideas that many investors overlook.

• Spot potential upside early by scanning for screener containing 20 high quality undiscovered gems that combine solid fundamentals with room for greater market attention.
• Strengthen your portfolio’s foundation by focusing on businesses in the solid balance sheet and fundamentals stocks screener (48 results) that can better handle pressure when conditions turn.
• Reduce stress and smooth your returns by concentrating on companies in the 65 resilient stocks with low risk scores instead of chasing every headline move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com